Wells Fargo Maintains Overweight on Cabaletta Bio, Raises Price Target to $39
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila has maintained an Overweight rating on Cabaletta Bio (NASDAQ:CABA) and raised the price target from $14 to $39.
September 18, 2023 | 12:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo has maintained an Overweight rating on Cabaletta Bio and raised the price target from $14 to $39, indicating a positive outlook for the company.
The raised price target from Wells Fargo indicates a strong positive outlook for Cabaletta Bio. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100